Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Clinical Pharmacology & Therapeutics2001Vol. 70(1), pp. 42–47
Citations Over TimeTop 10% of 2001 papers
Abstract
The polymorphic CYP2C19 appears to be a major enzyme involved in the N-demethylation of sertraline, and both extensive and poor metabolizers had marked differences in the disposition of sertraline.
Related Papers
- → Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms(2009)43 cited
- → Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects(2021)6 cited
- Esomeprazole Therapy and CYP2C19 Genotype(2016)
- → Evidence of Sex-related Differences in Cytochrome P450 2C19 and 3A4 Mediated Metabolism of Omeprazole: Observations in an Understudied Population in South-East Anatolia in Turkey(2013)
- PHARMACOKINETICS AND DISPOSITION(1999)